Two whistleblowers adequately alleged that
Jessica Penelow and Christone Brancaccio sufficiently argued that Janssen’s off-label promotion of Prezista and Intelence misled doctors about the drugs being appropriate for patients with lipid conditions, and therefore claims seeking reimbursement from the government were false, Judge Zahid N. Quraishi of the U.S. District Court for the District of New Jersey said in a Tuesday opinion.
There is a genuine issue of material fact as to ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.